MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.18
+0.61
+9.28%
After Hours: 7.70 +0.52 +7.24% 17:52 03/27 EDT
OPEN
6.06
PREV CLOSE
6.57
HIGH
7.54
LOW
6.06
VOLUME
250.75K
TURNOVER
--
52 WEEK HIGH
16.07
52 WEEK LOW
4.830
MARKET CAP
387.55M
P/E (TTM)
-4.6864
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PRQR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRQR stock price target is 27.57 with a high estimate of 40.84 and a low estimate of 20.42.

EPS

PRQR News

More
  • ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
  • GlobeNewswire · 2d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
  • Zacks · 03/05 13:29
  • 3 High-Risk, High-Reward Stocks That Have Massive Upside Potential
  • MotleyFool.com · 02/29 12:25

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About PRQR

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.